Word: ebert
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
During the summer of 1969, Ebert decided that his Squibb post might give the appearance of conflict of interest with his administrative duties. He decided to resign from the Board, but was persuaded by Squibb President Richard Furlaud, a personal friend, to remain with the company as a "public director" owning no stock and receiving no salary...
...when a group of medical school students protested in October 1969 that any association with the pharmaceutical company's board compromised "the first obligation of a physician or teacher of physicians...to the patient," Ebert resigned his post. "There are those," he said in explaining his decision, "who, in all sincerity, feel that my continued membership on the board could be subject to misinterpretation...
Three years later, Dean Ebert appeared before an FDA Advisory panel which was holding a hearing on Squibb's Mysteclin-F, a drug which had been severely criticized by a National Academy of Sciences-National Research Council panel of thirty specialists on infections diseases. Critics argued that prescription of Mysteclin-F's fixed combination of several antibiotics was irrational since it tended to give the patient too much or too little of each of the antibiotics, rather than the precise dosage needed...
Squibb needed big names to defend the embattled Mysteclin-F, and it called on two of the biggest names in academic medicine, both on the Squibb payroll: Dean Ebert (a Squibb consultant), and Dean Lewis Thomas of the Yale Medical School a member of the Squibb Board of Directors...
...Dean Ebert delivered the Squibb defense brief. He cited "additional evidence" compiled by physicians at the Roswell Park Memorial Cancer Institute in Buffalo. N.Y. which suggested that Mysteclin-F had some therapeutic value in the treatment of certain types of infections. Ebert suggested that the drug be labelled to indicate these specific usages...